Surgical Adjuvant Therapy of Non-Small-Cell Lung Cancer
Lung cancer is the leading cancer killer in the United States. One hundred forty thousand patients will develop lung cancer annually, and half of these patients will have disease confined to the thorax without clinical evidence of dissemination (figure 14.1). About 20% will have stage I disease, 30% will have more advanced local disease, some of whom can be resected surgically with a low expectation of cure, and others with tumor localized to the thorax will be technically unresectable. Surgery alone can cure most patients with T1N0 lesions, and about 60% of the patients with T2N0 and T1N1 tumors can be cured by surgical resection. Surgical treatment alone cures about half the patients with T2N1 squamous disease, and only 25% of the patients with T2N1 adenocarcinoma. A subset of patients with T3N2 disease can expect a favorable survival following surgical resection, but most patients in this category have technically unresectable disease (table 14.1) .
KeywordsToxicity Urea Platinum Adenocarcinoma Oncol
Unable to display preview. Download preview PDF.
- 5.Brunner KW, Marthaler T, Muller W: Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma. Cancer Chemother Rep 4:125–132, 1973.Google Scholar
- 7.The Lung Cancer Study Group (prepared by Lad T, Rubenstein L, Sadeghi A): The benefit of adjuvant treatment for resected local advanced non-small-cell lung cancer. J Clin Oncol 6:9–17, 1988.Google Scholar
- 8.Henderson IC: Adjuvant systemic therapy for early breast cancer. In: Haskell CM (ed): Current Problems in Cancer, Volume 9. 1987.Google Scholar
- 12.Greist A, Roth B, Einhorn L, et al: Cis-platinum combination chemotherapy for disseminated germ cell tumors: Long term follow-up. Proc Am Soc Clin Oncol 4:100 (Abst C-388), 1985.Google Scholar
- 14.The Lung Cancer Study Group (prepared by Eagan RT, Ruud C, Lee R, Pairolero P, Gail M): A pilot study of induction therapy with cyclophosphamide, doxorubicin, cis-platinum (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small-cell lung cancer. Cancer Treat Rep 71:895–900, 1987.PubMedGoogle Scholar
- 16.The Lung Cancer Study Group (prepared by Weiden P): Preoperative chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a phase II study of the Lung Cancer Study Group. Proc Am Soc Clin Oncol 6:185 (Abst 728), 1987.Google Scholar
- 17.Kris MG, Gralla RG, Martini N, Burke MT, McCormack P, Bains M, Kaiser L, Burt M, Heelan RT: Trial of preoperative Cisplatin plus vinca alkaloid chemotherapy in non-small-cell lung cancer (NSCLC) patients with clinically apparent, ipsilateral, mediastinal lymph node metastases. Proc Am Soc Clin Oncol 6:177 (Abst 697), 1987.Google Scholar
- 18.Overgaard J, Kahn AR: Selective enhancement of radiation response in a C3H mammary carcinoma by cis-platinum. Cancer 65:649, 1982.Google Scholar
- 20.Bonomi P, Sandler S, Bushy J, Reddy S: Adjuvant chemotherapy in locally advanced squamous cell bronchogenic carcinoma. Proc Am Soc Clin Oncol 3:228 (Abst C-892), 1984.Google Scholar